Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05070403 · ClinicalTrials.gov registry record · Phase 2
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
A Phase 2 study of Squamous Cell Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05070403 is a Phase 2 study of Squamous Cell Carcinoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 25 participants, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05070403, a Phase 2 study of Squamous Cell Carcinoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
Conditions Studied
Interventions
- DRUG Afatinib 40 MG
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05070403
The ClinicalTrials.gov registry entry for NCT05070403 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (76% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Afatinib 40 MG is the first listed.
NCT05070403 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05070403 about?
NCT05070403 is a clinical study titled "Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma". The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
What is the current status of trial NCT05070403?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-10-01. Estimated completion is 2028-03.
What conditions does trial NCT05070403 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05070403?
The interventions under investigation include: Afatinib 40 MG (DRUG).
Who is sponsoring clinical trial NCT05070403?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05070403 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.